title: Inhibition of lipopolysaccharide-induced proinflammatory responses by Buddleja officinalis extract in BV-2 microglial cells via negative regulation of NF-kB and ERK1/2 signaling.
abstract: Buddleja officinalis has been traditionally used in the supportive treatment of inflammatory and neuronal diseases in Korea and China. Although several reports have shown the anti-inflammatory effects of Buddleja officinalis, the anti-neuroinflammatory effect has remained unclear. In this study, we aimed to investigate the inhibitory effects of flower buds of B. officinalis Maximowicz water extract (BOWE) on LPS-induced inflammatory processes in BV-2 microglial cells. BOWE dose-dependently inhibited the production of nitric oxide as well as iNOS mRNA expression. Moreover, BOWE prevented IL-1β and IL-6 mRNA expression. However, BOWE had no effect on LPS-induced COX-2 or TNF-a mRNA expression. The extract also had no effect on LPS-stimulated p38 MAPK, JNK, and c-Jun phosphorylation, whereas ERK1/2 phosphorylation was strongly inhibited by BOWE. BOWE also inhibited the LPS-induced degradation of IkB-α, and LPS-induced phosphorylation of p65 NF-kB protein. These data indicate that BOWE inhibited the nitric oxide production and pro-inflammatory gene expression in BV-2 microglial cells, possibly through a negative regulation of the NF-kB and ERK1/2 pathways. Further identification of the direct target molecule(s) of BOWE is required to support its use as an anti-neuroinflammatory agent against the neurodegenerative disorders.
authors.affiliation: Radiation Biotechnology Research Division, Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute-KAERI, 1266 Sinjeong-dong Jeongeup-si, Jeonbuk 580-185, Korea.
authors.forename: Won-Jun
authors.initials: WJ
authors.lastname: Oh
authors.forename: Uhee
authors.initials: U
authors.lastname: Jung
authors.forename: Hyun-Soo
authors.initials: HS
authors.lastname: Eom
authors.forename: Hee-June
authors.initials: HJ
authors.lastname: Shin
authors.forename: Hae-Ran
authors.initials: HR
authors.lastname: Park
mesh_terms: D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000494:pharmacology*; D032861:Buddleja / Q000737:chemistry*; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy*; D008070:Lipopolysaccharides / Q000633:toxicity; D020935:MAP Kinase Signaling System / Q000187:drug effects; D017628:Microglia / Q000166:cytology / Q000187:drug effects; D016328:NF-kappa B / Q000187:drug effects; D009569:Nitric Oxide / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D000893:Anti-Inflammatory Agents; D008070:Lipopolysaccharides; D016328:NF-kappa B; D010936:Plant Extracts; D009569:Nitric Oxide; C496319:NOS2 protein, human; D052247:Nitric Oxide Synthase Type II
references.citation: Neuropsychopharmacology. 2007 Dec;32(12):2570-80
references.pmid: 17356569
references.citation: Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S421-6
references.pmid: 16237641
references.citation: J Pineal Res. 2010 May;48(4):347-52
references.pmid: 20374443
references.citation: Immunology. 2008 Nov;125(3):344-58
references.pmid: 18422969
references.citation: Bioorg Med Chem. 2011 Jul 1;19(13):4021-7
references.pmid: 21652214
references.citation: Neurochem Int. 2006 Jul;49(2):170-82
references.pmid: 16765486
references.citation: Brain Res Rev. 2007 Jun;54(2):274-85
references.pmid: 17383006
references.citation: J Neurochem. 2009 Mar;108(6):1343-59
references.pmid: 19154336
references.citation: FEBS Lett. 2006 Sep 18;580(21):4984-90
references.pmid: 16949582
references.citation: Antioxid Redox Signal. 2006 May-Jun;8(5-6):929-47
references.pmid: 16771683
references.citation: Biol Pharm Bull. 2006 Aug;29(8):1608-12
references.pmid: 16880613
references.citation: Bioorg Med Chem Lett. 2011 Jun 1;21(11):3462-6
references.pmid: 21524582
references.citation: Life Sci. 2005 Aug 12;77(13):1502-15
references.pmid: 15979653
references.citation: Food Chem Toxicol. 2013 Mar;53:376-83
references.pmid: 23266501
references.citation: Mol Aspects Med. 2005 Feb-Apr;26(1-2):33-65
references.pmid: 15722114
references.citation: Cell. 2008 Feb 8;132(3):344-62
references.pmid: 18267068
references.citation: Int Immunopharmacol. 2010 Dec;10(12):1560-72
references.pmid: 20932499
references.citation: Biochim Biophys Acta. 2005 Dec 30;1754(1-2):253-62
references.pmid: 16198162
references.citation: Cell Immunol. 2011;268(2):112-6
references.pmid: 21420072
references.citation: Glia. 2002 Nov;40(2):232-9
references.pmid: 12379910
references.citation: Exp Cell Res. 2008 Jul 1;314(11-12):2187-98
references.pmid: 18508047
references.citation: Biochem Biophys Res Commun. 2011 Mar 18;406(3):488-92
references.pmid: 21338578
references.citation: Exp Mol Med. 2006 Aug 31;38(4):333-47
references.pmid: 16953112
references.citation: Mol Oral Microbiol. 2012 Jun;27(3):149-59
references.pmid: 22520385
references.citation: Behav Brain Res. 2010 May 1;209(1):165-73
references.pmid: 20122965
references.citation: Free Radic Biol Med. 2008 Dec 15;45(12):1695-704
references.pmid: 18852043
references.citation: Neurochem Int. 2006 Jan;48(1):60-6
references.pmid: 16298020
references.citation: Lancet Oncol. 2001 Mar;2(3):149-56
references.pmid: 11902565
references.citation: J Pharmacol Exp Ther. 2003 Jan;304(1):1-7
references.pmid: 12490568
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2003 Aug;27(5):741-9
references.pmid: 12921904